Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial

This clinical trial studies whether measuring circulating tumor deoxyribonucleic acid (ctDNA) tumor fraction (TF) can be used to help guide the early stopping (discontinuation) of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) in patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Many types of tumors tend to lose cells or release different types of cellular products including their deoxyribonucleic acid, which is referred to as ctDNA, into the bloodstream before changes can be seen on s

Trial Details

NCT ID
NCT07698535
Phase
PHASE2
Sponsor
University of Washington
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Lutetium Lu 177 Vipivotide Tetraxetan
  • Cell-free Circulating Tumor DNA Assay
  • Computed Tomography
  • Docetaxel
  • PSMA PET Scan
  • Single Photon Tomography and Computed Tomography Scan
Locations (sample)
  • Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

  • Willing and able to provide informed consent
  • Adult males ≥ 18 years age
  • History of histologically confirmed adenocarcinoma of the prostate without evidence of neuroendocrine or small cell differentiation. If histology i…
  • Evidence of metastatic disease on bone scan or CT scan

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →